Thank you, Howard, and good morning, everyone. In 2023, we delivered organic net sales growth of nearly 3%, which included a 3.2% volume headwind from SKU rationalization, increased adjusted EBITDA by 10% to $187 million and expanded adjusted EBITDA margins 90 basis points to 13%. I'm proud of our team's efforts during a dynamic consumer environment to deliver these results. In the fourth quarter, organic net sales slightly declined 30 basis points and adjusted EBITDA increased 12% as our productivity programs and actions to optimize our network and portfolio are delivering stronger profitability. Importantly, our organic net sales growth combined with these actions resulted in our fourth consecutive quarter of adjusted EBITDA margin expansion, as we delivered 14% adjusted EBITDA margins in the quarter. During the quarter, our organic net sales performance was led by volume mix growth of 50 basis points. Volume was impacted as expected by 2.5% due to SKU reductions. When we adjust for SKU rationalization, we estimate that our volume mix grew 3% in the quarter, which is an acceleration from 2.7% last quarter. Our broad based SKU rationalization actions are now complete and in 2024, we don't expect this program to be a material impact to our results. Additionally, as we discussed last quarter, our fourth quarter net sales were negatively impacted by some earlier holiday shipments that were originally forecasted to occur in the fourth quarter, but shipped in the third quarter. Offsetting the volume increase in the quarter was a pricing decline of 80 basis points as we lapped 17% price realization in the prior year. Also, we made certain price pack architecture adjustments to be better positioned in the market. Finally, our total net sales growth was impacted by the conversion of company-owned RSP routes to independent operators, which reduced growth by 40 basis points. Similar to SKU rationalization, this program is now complete and will have a small impact of 30 basis points in the first half fiscal 2024 sales growth as we lap out of last year's conversion. Moving down the P&L, adjusted gross margin expanded 52 basis points in the fourth quarter, which I'll note included a 40 basis points headwind from our conversion to IO routes. Excluding this impact, adjusted gross margins expanded year-over-year by over 90 basis points led by our productivity programs, which more than offset commodity and labor inflation. In addition, our SKU rationalization programs improved our margin mix as we reduced lower margin private label and partner brand SKUs. Adjusted SG&A expense declined 5.1%, an improvement of 110 basis points as a percent of sales, as a result of our productivity initiatives focused on logistics and lower administrative spend. As our sales growth normalizes, we have been able to manage spend through cost control measures in addition to driving productivity within our selling and logistics costs. Partially offsetting these factors were continued investments in e-commerce, people, selling infrastructure and supply chain capabilities to support our growth. Bringing it together, adjusted EBITDA increased by 12% to $49.4 million and margins expanded 160 basis points to 14% of sales. The margin expansion was driven by 350 basis points of productivity, 70 basis points from selling and admin expenses and 20 basis points of volume mix. These benefits were partially offset by 200 basis points of inflation and 80 basis points of pricing. In addition, adjusted net income increased 6.5% and adjusted EPS increased by 6.7% to $0.16 per share. Stronger operating earnings were partially offset by a less favorable tax rate and higher interest expense, primarily due to higher rates on our floating rate debt. Turning to cash flow and the balance sheet. Consistent with normal seasonality and from our cross functional efforts to improve our cash conversion cycle, we generated strong cash in the second half of the year of over $80 million. I'm happy to report that our transformation efforts in this important area are working and we are now seeing the benefits in our results. This resulted in cash flow from operations in the full year of $76.6 million. We also remain committed to our capital priorities and capital expenditures were $55.7 million, primarily related to supporting our productivity programs and our investments in our Kings Mountain manufacturing plant. In addition, we have paid $32.1 million in dividends and distribution to shareholders. Finishing with the balance sheet, cash on hand was $52 million and our liquidity remains strong at over $210 million giving us ample financial flexibility. Net debt at quarter end was $866.7 million or 4.6x trailing 12 months normalized adjusted EBITDA of $187.2 million. This was slightly higher than our expectations. That said, on February 5, we closed the previously announced disposition transaction of the Good Health and R.W. Garcia brands and three manufacturing facilities. The transaction included a total consideration of $182.5 million with approximately $150 million in after tax proceeds, which we immediately used to pay down long-term debt of which more than 90% apply to our floating rate term loan. This single debt repayment resulted in about $12 million in lower interest expense for 2024 and notably, our fixed rate debt now comprises approximately 80% of our total debt, up from 70% at year-end. Importantly and consistent with our strategy, this accelerates our timeframe to achieving our target of 3x net leverage ratio to year-end 2025, a year ahead from year-end 2026 target that set at Investor Day in December. Now turning to our full year outlook for fiscal 2024. I believe our 2024 outlook positions us well to deliver our 2026 financial targets that we set out at our Investor Day. We expect organic net sales to increase approximately 3% or better, which reflects our outlook for normalizing salty snack category growth. Our growth is expected to be led by volume with outsized strength in our expansion geographies and pricing about flat for the year. Turning to total net sales. Our growth in 2024 is estimated to be impacted by about $45 million due to the disposition of the Good Health and R.W. Garcia brands. You will recall that the total combined sales for these brands for the full-year 2023 was approximately $65 million. Given we have a DST agreement with the new owner, Our Home, to continue to distribute Good Health. This results in a lower impact to our total sales in 2024. From a weighting standpoint, we expect about a 49% to 51% first half versus second half split for our net sales. Moving to adjusted EBITDA, we expect growth of 5% to 8%, fueled by gross margin expansion as our base productivity programs and network optimization cost savings build. In addition, our 2024 outlook assumes a roughly 40% increase in market expense, which is consistent with what we laid out during our Investor Day. Our outlook includes an estimated impact of foregone contribution to adjusted EBITDA from our brand disposition, which I'll note is mostly offset by cost savings and also our transition services agreement. We expect first half versus second half weighting of adjusted EBITDA to be similar to last year. Adjusted earnings per share is expected to increase 16% to 21%, led by stronger operating earnings and lower interest expense due to the recent debt pay down from the disposition net cash proceeds. Additionally, we expect our adjusted effective tax rate to be between 19% to 21%, interest expense of approximately $50 million and capital investments of between $80 million and $90 million. As we outlined at our Investor Day, we expect CapEx over the next three years to be about 5% of total net sales. This outlook is unchanged, but the pacing has been accelerated, increasing our 2024 spend given our recent plant dispositions and the need to more quickly invest in our key facilities where production will be transitioned. For example, incremental CapEx this year will be focused on installing a new Tortilla chip line in Hanover and automation projects such as palletizers and case erectors. These actions will accelerate network optimization savings to help fully offset the adjusted EBITDA sold by 2025. Finally, we expect net leverage of approximately 3.6x in 2024, a full term improvement from 2023. Our 2024 outlook and improved capital structure position us well to deliver our 3-year goals. More importantly, the entire Utz team is working together to deliver our category leading opportunity ahead of us. Now, I would like to turn the call back over to Howard, who will talk more about the year ahead. Howard?